Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2021 Feb 08

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Medica 2021 Feb 08

DOI: 10.23736/S0026-4806.21.07353-5

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Cerebral venous thrombosis

Omri COHEN 1, 2, 3 , Samuela PEGORARO 3, Walter AGENO 3

1 National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel; 2 Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 3 Department of Medicine and Surgery, University of Insubria, Varese, Italy


PDF


Cerebral venous thrombosis (CVT) is a rare form of deep venous thrombosis (DVT), yet a leading cause of stroke in young adults, with an incidence that seems to be increasing in recent years. Risk factors for CVT overlap with those of DVT in other locations, with the addition of local risk factors, such as infections, head trauma and neurosurgery. The clinical presentation is highly variable, hence the diagnosis of CVT may be delayed or overlooked. Early recognition and timely initiation of anticoagulant treatment are of essence, while decompressive surgery can be lifesaving for patients with impending transtentorial herniation. Concomitant intracranial hemorrhage is not a contraindication to anticoagulant treatment. Endovascular treatment may be suggested for selected patients who deteriorate despite anticoagulant treatment. In this review we will provide an extensive and contemporary discussion of the incidence, pathophysiology, risk factors, clinical presentation, neuroimaging and management of CVT, in accordance with recent guidelines. Additionally, we will summarize the latest data with regards to direct oral anticoagulants (DOACs) treatment in CVT.


KEY WORDS: Cerebral venous thrombosis; Venous thromboembolism ; Anticoagulation

top of page